# Encompass Health Corp: overview

EHC · NYSE · CIK 785161 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ehc.md) · [Financials](/companies/ehc/financials.md) · [Filings](/companies/ehc/filings.md) · [Insiders](/companies/ehc/insiders.md)

Latest reported revenue: [$1.60bn](/filings/0000785161-26-000186.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000785161-26-000186).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,351](/filings/0000785161-25-000115.md) | [1,405 d](/filings/0000785161-26-000081.md) | [1,455](/filings/0000785161-26-000130.md) | [1,458](/filings/0000785161-26-000186.md) | [1,478](/filings/0000785161-25-000115.md) | [1,545 d](/filings/0000785161-26-000081.md) | [1,587](/filings/0000785161-26-000130.md) | [1,597](/filings/0000785161-26-000186.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [8.0%](/filings/0000785161-25-000115.md) | [8.6% d](/filings/0000785161-26-000081.md) | [10.4%](/filings/0000785161-26-000130.md) | [9.7%](/filings/0000785161-26-000186.md) | [8.6%](/filings/0000785161-25-000115.md) | [9.5% d](/filings/0000785161-26-000081.md) | [12.3%](/filings/0000785161-26-000130.md) | [9.6%](/filings/0000785161-26-000186.md) |
| Diluted EPS | $ per share | [1.06](/filings/0000785161-25-000115.md) | not reported | [1.48](/filings/0000785161-26-000130.md) | [1.39](/filings/0000785161-26-000186.md) | [1.24](/filings/0000785161-25-000115.md) | not reported | [1.93](/filings/0000785161-26-000130.md) | [1.54](/filings/0000785161-26-000186.md) |
| Free cash flow | $m | [120 d](/filings/0000785161-25-000115.md) | [80.1 d](/filings/0000785161-26-000081.md) | [126](/filings/0000785161-26-000130.md) | [113 d](/filings/0000785161-26-000186.md) | [83.7 d](/filings/0000785161-25-000115.md) | [117 d](/filings/0000785161-26-000081.md) | [151](/filings/0000785161-26-000130.md) | [62.3 d](/filings/0000785161-26-000186.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,015](/filings/0000785161-24-000009.md) | [4,349](/filings/0000785161-25-000009.md) | [4,801](/filings/0000785161-26-000081.md) | [5,373](/filings/0000785161-26-000081.md) | [5,935](/filings/0000785161-26-000081.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [13.9%](/filings/0000785161-23-000012.md) | [12.4%](/filings/0000785161-23-000012.md) | not reported | not reported | not reported |
| Net margin | % | [10.3%](/filings/0000785161-24-000009.md) | [6.2%](/filings/0000785161-25-000009.md) | [7.3%](/filings/0000785161-26-000081.md) | [8.5%](/filings/0000785161-26-000081.md) | [9.5%](/filings/0000785161-26-000081.md) |
| Diluted EPS | $ per share | [4.11](/filings/0000785161-24-000009.md) | [2.70](/filings/0000785161-25-000009.md) | [3.47](/filings/0000785161-26-000081.md) | [4.46](/filings/0000785161-26-000081.md) | [5.54](/filings/0000785161-26-000081.md) |
| Free cash flow | $m | [191](/filings/0000785161-23-000012.md) | [141](/filings/0000785161-23-000012.md) | [268](/filings/0000785161-26-000081.md) | [360](/filings/0000785161-26-000081.md) | [439](/filings/0000785161-26-000081.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ehc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.06bn | 10,484,385 |  | Reduced −284,328 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $497.8m | 4,924,664 |  | Reduced −34,881 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $452.4m | 4,475,896 |  | Added +9,659 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $331.4m | 3,278,739 |  | Reduced −570,116 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $322.0m | 3,185,798 |  | Added +40,824 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $259.1m | 2,563,104 |  | Added +2,051,217 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $248.7m | 2,460,657 |  | Added +230,678 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $239.1m | 2,471,751 |  | Reduced −149,494 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $229.2m | 2,267,668 |  | Added +45,567 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $191.2m | 1,890,743 |  | Reduced −7,924 |

## Recent filings

[All 2,069 filings](/companies/ehc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 20:39 ET | [8-K](/filings/0000785161-26-000195.md) | 8.01 Other events | 0000785161-26-000195 |
| 2026-08-07 | 17:12 ET | [10-Q](/filings/0000785161-26-000186.md) | Quarterly report, period 2026-06-30 | 0000785161-26-000186 |
| 2026-08-05 | 20:23 ET | [8-K](/filings/0000785161-26-000183.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000785161-26-000183 |
| 2026-06-01 | 20:26 ET | [8-K](/filings/0000785161-26-000161.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000785161-26-000161 |
| 2026-05-15 | 19:24 ET | [8-K](/filings/0000785161-26-000156.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000785161-26-000156 |
| 2026-05-11 | 20:21 ET | [8-K](/filings/0000785161-26-000151.md) | 5.07 Shareholder vote results | 0000785161-26-000151 |
| 2026-05-01 | 19:28 ET | [10-Q](/filings/0000785161-26-000130.md) | Quarterly report, period 2026-03-31 | 0000785161-26-000130 |
| 2026-04-30 | 20:24 ET | [8-K](/filings/0000785161-26-000128.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000785161-26-000128 |
| 2026-04-07 | 13:58 ET | [DEF 14A](/filings/0000785161-26-000105.md) | Proxy statement, period 2026-05-07 | 0000785161-26-000105 |
| 2026-03-10 | 20:49 ET | [8-K](/filings/0000785161-26-000100.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000785161-26-000100 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000785161-26-000081.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ceea2355-c504-4c0c-89c1-b2833737b2a1)

## About the filer

- CIK: 785161
- Tickers: EHC
- Exchange: NYSE
- SIC code: 8060 Services-Hospitals
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.